T. Rowe Price Associates’s Entellus Medical, Inc. Common Stock ENTL Stock Holding History

T. Rowe Price Associates’s Portfolio ENTL Stock Details ENTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,188,524	Closed	-$16.4M	–	2598
2017 Q1	$16.4M	Buy	1,188,524 +861,291	+263%	+$13.8M	﹤0.01%	1232
2016 Q4	$6.21M	Buy	327,233 +1,000	+0.3%	+$19.2K	﹤0.01%	1393
2016 Q3	$7.24M	Sell	326,233 -1,049	-0.3%	-$19.7K	﹤0.01%	1374
2016 Q2	$5.98M	Buy	327,282 +65,000	+25%	+$1.12M	﹤0.01%	1372
2016 Q1	$4.77M	Sell	262,282 -4,360	-2%	-$70.5K	﹤0.01%	1408
2015 Q4	$4.5M	Buy	266,642 +8,610	+3%	+$146K	﹤0.01%	1430
2015 Q3	$4.65M	Buy	258,032 +38,163	+17%	+$850K	﹤0.01%	1446
2015 Q2	$5.69M	Sell	219,869 -12,343	-5%	-$312K	﹤0.01%	1456
2015 Q1	$5.08M	Buy	+232,212	New	+$5.01M	﹤0.01%	1468

Other funds holding ENTL

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

DGI

Discovery Group I Chicago, Illinois $262M AUM 29.24% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates's ENTL Position: Q2 2017 in Review

T. Rowe Price Associates sold out of Entellus Medical, Inc. Common Stock (ENTL) in Q2 2017, closing a stake of 1,188,524 shares — an estimated $16.4M sold.

T. Rowe Price Associates first reported a position in ENTL in Q1 2015 and held it in 9 quarters. The position peaked at $16.4M in Q1 2017. 73 funds tracked by Wall St. Rank hold ENTL as of Q2 2017.

T. Rowe Price Associates reported no remaining Entellus Medical, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
T. Rowe Price Associates sold 1,188,524 Entellus Medical, Inc. Common Stock shares in Q2 2017, an estimated $16.4M.
T. Rowe Price Associates first reported a position in Entellus Medical, Inc. Common Stock in Q1 2015 and held it in 9 quarters.
T. Rowe Price Associates's Entellus Medical, Inc. Common Stock position peaked at $16.4M in Q1 2017.
73 funds tracked by Wall St. Rank held Entellus Medical, Inc. Common Stock as of Q2 2017.

Based on T. Rowe Price Associates's 13F filing for Q2 2017, filed 14 Aug 2017.